All In Biotech

Drug Trial Radar · NCT01438112

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With NMIBC With Carcinoma In Situ Disease Who Have Failed BCG

Last checked: Nov 20, 2026Latest source record: Apr 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

22

Actual

Start

Mar 2014

Primary completion

Jun 2016

Study completion Jun 2016

Sponsor

Lead sponsor
CG Oncology, Inc.Industry
Sponsor type
Industry
First posted
Sep 21, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It forms the hypothesis that this regimen may be used for people who have failed current forms of treatment and are recommended for cystectomy. It is with hope that this novel therapy will be able to delay or potentially avoid cystectomy for this patient population. Bladder instillation of this agent causes little long lasting side effects and may drastically improve the stimulation of the immune system for local cancer cell death as well as destroying those tumor cells that may have travelled to regional lymph nodes or distant organs.

Conditions

  • Transitional Cell Carcinoma
  • Bladder Cancer
  • Carcinoma in Situ
  • Carcinoma in Situ Concurrent With Papillary Tumors

Interventions

  • CG0070 Adenovirus VectorBiological

    CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six

  • Control Arm: Quadruple ChoiceOther

    Quadruple Choice Treatment Options: (same as listed above)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response Proportion (CR)Time frame: 9 months (Phase II)
  2. Durable Complete Response Proportion (DCR)Time frame: 15 months (Phase III)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • BCG Oncology

    Phoenix, Arizona

  • University of California, San Diego- Moores Cancer Center

    La Jolla, California

  • UCLA Institute of Urological Oncology

    Los Angeles, California

  • University of California, Davis- Cancer Center

    Sacramento, California

  • University of Chicago, Department of Surgery, Section of Urology

    Chicago, Illinois

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Vanderbilt University Medical Center Department of Urologic Surgery

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.